In his first big merger of the year, Charles Ruck helped biotechnology giant Amgen Inc. acquire the biotech company Tularik Inc. for $1.3 billion.
Ruck is a mergers and acquisitions partner in the corporate department of Latham & Watkins. In 2002, Ruck served on the team that guided Amgen Inc.’s $17.7 billion merger with the drug company Immunex. Founded in 1980, Amgen creates products with the latest advancements in molecular biology, and now bills itself as the world’s largest biotechnology company. He also advised the pharmaceutical company TheraSense when it was acquired by Abbott Laboratories in a billion-dollar deal.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]